Vericel Corporation (VCEL) is a publicly traded Healthcare sector company. As of November 5, 2026, VCEL trades at $48.75 with a market cap of $2.10B and a P/E ratio of 83.60. VCEL moved +7.19% today. Year to date, VCEL is +22.64%; over the trailing twelve months it is +25.45%. Its 52-week range spans $28.95 to $49.32. Analyst consensus is strong buy with an average price target of $56.33. Rallies surfaces VCEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vericel revenue rose 26% to $85.37 million as MACI sales drove growth: Vericel’s third-quarter revenue rose 26% year over year to $85.37 million, beating the $77.95 million estimate, while net income climbed 179% to $14.16 million. It raised 2026 revenue guidance to $344 million–$346 million and increased its MACI and Burn Care outlooks.
| Metric | Value |
|---|---|
| Price | $48.75 |
| Market Cap | $2.10B |
| P/E Ratio | 83.60 |
| EPS | $0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $49.32 |
| 52-Week Low | $28.95 |
| Volume | 5.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $306.30M |
| Net Income | $24.22M |
| Gross Margin | 74.56% |
3 analysts cover VCEL: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.33.